+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neuroscience Market by Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5889272
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Neuroscience Market grew from USD 13.77 billion in 2023 to USD 15.11 billion in 2024. It is expected to continue growing at a CAGR of 10.34%, reaching USD 27.42 billion by 2030.

Neuroscience, the study of the nervous system, spans various disciplines such as neurobiology, cognitive neuroscience, and computational neuroscience, focusing on brain functionality and its impact on behavior and cognitive processes. The ever-growing necessity for neuroscience arises from increasing neurological disorders, a rising aging population, and the demand for advanced healthcare treatment methods. With applications in pharmaceuticals, biotech, and even artificial intelligence, neuroscience plays a crucial role in developing diagnostics, therapeutic solutions, and brain-machine interfaces. The end-use scope primarily targets healthcare institutions, research institutes, and technology companies. Key influencing growth factors include advancements in neuroimaging technologies, heightened investments in R&D, and increased governmental support. Potential opportunities lie in the integration of AI with neurological research, personalized medicine, and non-invasive brain stimulation therapies. To seize these opportunities, companies should focus on strategic collaborations with tech innovators and accumulate interdisciplinary expertise. However, the market faces limitations such as high research costs, ethical considerations in brain-related studies, and stringent regulatory frameworks. These challenges necessitate cautious navigation but also provide incentives for innovative breakthroughs. The areas ripe for innovation include the development of AI-driven neuroimaging tools for early diagnosis, neuroinformatics for big data analysis of brain activity, and enhanced neural prosthetics. Engaging in explorative research that bridges technology, biology, and data analytics will be vital for business growth. The market is dynamic, with high competition and rapid technological advancements, urging stakeholders to maintain agility in adopting emerging trends. To thrive, companies must leverage collaborations, invest in cutting-edge technologies, and refine their approaches according to insights derived from extensive market analysis. Continued exploration into brain health and cognitive enhancement is not only promising in terms of financial investment but also crucial in addressing far-reaching societal health challenges.

Understanding Market Dynamics in the Neuroscience Market

The Neuroscience Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing prevalence of neurological disorders worldwide
    • Rise in drug discovery and development for neurological conditions
    • Increasing use of neuroscience to enhance brain health and cognitive functions
  • Market Restraints
    • High cost associated with neuroscience research
  • Market Opportunities
    • Emerging use of neuroscience in the development of personalized medicine
    • Favorable funding landscape for neuroscience research
  • Market Challenges
    • Functional limitations pertaining to the use of neurotechnologies

Exploring Porter’s Five Forces for the Neuroscience Market

Porter’s Five Forces framework further strengthens the insights of the Neuroscience Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Neuroscience Market

External macro-environmental factors deeply influence the performance of the Neuroscience Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Neuroscience Market

The Neuroscience Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Neuroscience Market

The Neuroscience Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Neuroscience Market

The Neuroscience Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroscience Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Brain Products GmbH, Compumedics Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilson, Inc., GL Sciences Inc., Hitachi, Ltd., Illumina, Inc., JASCO Corporation, Merck KGaA, Metrohm AG, Natus Medical Incorporated, Novasep Holding SAS, PerkinElmer Inc., Pfizer Inc., Promega Corporation, QIAGEN GmbH, Restek Corporation, Shimadzu Corporation, Siemens AG, Thermo Fisher Scientific Inc., Waters Corporation, and YMC Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroscience Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Diagnostic Solution
      • Molecular
        • Immunoassay
        • Instruments
        • Kits & Consumables
        • Liquid Chromatography
        • PCR
        • Sequencing
        • Software
      • Non-molecular
        • Brainstem auditory evoked potential
        • Electroencephalography
        • Imaging
    • Drug Therapy
      • Neurological disorders
        • Alzheimer's disease
        • Epilepsy
        • Huntington's disease
        • Multiple sclerosis
        • Parkinson's disease
        • Vascular dementia
      • Neuropsychiatric disorders
        • Anxiety
        • Attention deficit
        • Autism spectrum
        • Insomnia
        • Mood disorder
        • Substance abuse
    • Non-drug Therapy
      • Behavioral Therapy
        • Animal-assisted
        • Home-based
        • Inpatient
        • Outpatient
      • Digital Health Services
  • End-User
    • Diagnostic Laboratories
    • Hospitals
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of neurological disorders worldwide
5.1.1.2. Rise in drug discovery and development for neurological conditions
5.1.1.3. Increasing use of neuroscience to enhance brain health and cognitive functions
5.1.2. Restraints
5.1.2.1. High cost associated with neuroscience research
5.1.3. Opportunities
5.1.3.1. Emerging use of neuroscience in the development of personalized medicine
5.1.3.2. Favorable funding landscape for neuroscience research
5.1.4. Challenges
5.1.4.1. Functional limitations pertaining to the use of neurotechnologies
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Neuroscience Market, by Type
6.1. Introduction
6.2. Diagnostic Solution
6.2.1. Molecular
6.2.1.1. Immunoassay
6.2.1.2. Instruments
6.2.1.3. Kits & Consumables
6.2.1.4. Liquid Chromatography
6.2.1.5. PCR
6.2.1.6. Sequencing
6.2.1.7. Software
6.2.2. Non-molecular
6.2.2.1. Brainstem auditory evoked potential
6.2.2.2. Electroencephalography
6.2.2.3. Imaging
6.3. Drug Therapy
6.3.1. Neurological disorders
6.3.1.1. Alzheimer's disease
6.3.1.2. Epilepsy
6.3.1.3. Huntington's disease
6.3.1.4. Multiple sclerosis
6.3.1.5. Parkinson's disease
6.3.1.6. Vascular dementia
6.3.2. Neuropsychiatric disorders
6.3.2.1. Anxiety
6.3.2.2. Attention deficit
6.3.2.3. Autism spectrum
6.3.2.4. Insomnia
6.3.2.5. Mood disorder
6.3.2.6. Substance abuse
6.4. Non-drug Therapy
6.4.1. Behavioral Therapy
6.4.1.1. Animal-assisted
6.4.1.2. Home-based
6.4.1.3. Inpatient
6.4.1.4. Outpatient
6.4.2. Digital Health Services
7. Neuroscience Market, by End-User
7.1. Introduction
7.2. Diagnostic Laboratories
7.3. Hospitals
7.4. Research & Academic Institutes
8. Americas Neuroscience Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Neuroscience Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Neuroscience Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NEUROSCIENCE MARKET RESEARCH PROCESS
FIGURE 2. NEUROSCIENCE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NEUROSCIENCE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NEUROSCIENCE MARKET DYNAMICS
TABLE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY BRAINSTEM AUDITORY EVOKED POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEUROSCIENCE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEUROSCIENCE MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEUROSCIENCE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEUROSCIENCE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEUROSCIENCE MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEUROSCIENCE MARKET SIZE, BY ATTENTION DEFICIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEUROSCIENCE MARKET SIZE, BY AUTISM SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOOD DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEUROSCIENCE MARKET SIZE, BY SUBSTANCE ABUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANIMAL-ASSISTED, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOME-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEUROSCIENCE MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEUROSCIENCE MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIGITAL HEALTH SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. CANADA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 88. CANADA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 89. CANADA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 90. CANADA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 91. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 92. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 93. CANADA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 94. CANADA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 95. CANADA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. MEXICO NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 98. MEXICO NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 99. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 100. MEXICO NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 104. MEXICO NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 128. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. CHINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. CHINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 140. CHINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 141. CHINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 142. CHINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 143. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 144. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 145. CHINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 146. CHINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 147. CHINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. INDIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. INDIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 150. INDIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 151. INDIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 152. INDIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 153. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 154. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 155. INDIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 156. INDIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 157. INDIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. INDONESIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. INDONESIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. JAPAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. JAPAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 170. JAPAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 171. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 172. JAPAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 173. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 174. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 175. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 176. JAPAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 177. JAPAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. MALAYSIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 180. MALAYSIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 181. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 182. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 183. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 190. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 191. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 192. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 193. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 194. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 195. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. SINGAPORE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 199. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 200. SINGAPORE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 201. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 202. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 203. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 204. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 205. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 206. SINGAPORE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 210. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 211. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 212. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 213. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 214. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 215. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 216. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 217. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. TAIWAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. TAIWAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 220. TAIWAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 221. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 222. TAIWAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 223. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 224. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 225. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 226. TAIWAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 227. TAIWAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. THAILAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. THAILAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 230. THAILAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 231. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 232. THAILAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 233. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 234. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 235. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 236. THAILAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 237. THAILAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. VIETNAM NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 239. VIETNAM NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 240. VIETNAM NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 241. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 242. VIETNAM NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 243. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 244. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 245. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 246. VIETNAM NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 247. VIETNAM NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 259. DENMARK NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 260. DENMARK NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 261. DENMARK NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 262. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 263. DENMARK NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 264. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 266. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 267. DENMARK NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 268. DENMARK NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. EGYPT NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 271. EGYPT NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 272. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 273. EGYPT NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 274. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 276. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 277. EGYPT NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 278. EGYPT NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. FINLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 280. FINLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 281. FINLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 282. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 283. FINLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 284. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 287. FINLAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 288. FINLAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 289. FRANCE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 290. FRANCE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 291. FRANCE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 292. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 293. FRANCE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 294. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 295. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 296. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 297. FRANCE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 298. FRANCE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 299. GERMANY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 300. GERMANY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 301. GERMANY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 302. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 303. GERMANY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 304. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 305. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 306. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 307. GERMANY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 308. GERMANY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 309. ISRAEL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 310. ISRAEL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 311. ISRAEL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 312. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 313. ISRAEL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 319. ITALY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 320. ITALY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 321. ITALY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 322. ITALY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 323. ITALY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 324. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 325. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 326. ITALY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 327. ITALY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 328. ITALY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 330. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 331. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 332. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 333. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 334. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 335. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 336. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 337. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 338. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 343. NIGERIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 344. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 345. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 346. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 347. NIGERIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 348. NIGERIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 349. NORWAY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 350. NORWAY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 351. NORWAY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 352. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 353. NORWAY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 354. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 355. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 356. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 357. NORWAY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
TABLE 358. NORWAY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 359. POLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 360. POLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
TABLE 361. POLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 362. POLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
TABLE 363. POLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 364. POLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2

Companies Mentioned

The leading players in the Neuroscience Market, which are profiled in this report, include:
  • Agilent Technologies, Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Brain Products GmbH
  • Compumedics Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilson, Inc.
  • GL Sciences Inc.
  • Hitachi, Ltd.
  • Illumina, Inc.
  • JASCO Corporation
  • Merck KGaA
  • Metrohm AG
  • Natus Medical Incorporated
  • Novasep Holding SAS
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Promega Corporation
  • QIAGEN GmbH
  • Restek Corporation
  • Shimadzu Corporation
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • YMC Co., Ltd.

Methodology

Loading
LOADING...

Table Information